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Background: Benzydamine, a non-steroidal anti-inflammatory drug (NSAID) in use for more than four
decades, has been reported to cause photosensitivity.
Objectives: To study the results of photopatch testing to benzydamine and the clinical features of the
dermatitis during a 3-year period (2006–2008).
Patients and methods: During this period, 74 patients with photodermatoses were photopatch tested with
an extended baseline series of allergens including benzydamine and in suspicious cases, with drugs that
contain it. Test sites were irradiated on D2 with 5 J/cm2 and readings were performed on D2 and D4.
Results: Ten patients (six females/four males), aged 21–84 years (mean 64.9) had a positive photopatch
test to benzydamine [1–5% petrolatum (pet.) from Bial-Aristegui®] and to drugs that contain it (Tantum
verde® oral solution and Momen® gel). Nine patients had lower lip cheilitis and one lichenified eczema
on photo-exposed sites.
Conclusion: Photosensitivity from both topical and systemic benzydamine has been occasionally
described, mainly in southern Spain. Despite its widespread use and its known photosensitizing capacity,
photoallergic contact dermatitis from benzydamine is probably underdiagnosed as the clinical presentation
of mainly the lip and chin is not typical of photoallergic contact dermatitis and benzydamine is not part
of most photoallergen series.
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Benzydamine (CAS number 642-72-8) is an
indazole non-steroidal anti-inflammatory drug
(NSAID) that has analgesic, anti-inflammatory,
and antipyretic properties and has been widely used
across Europe for nearly four decades (1). Benzy-
damine is available as a mouth wash for the relief of
sore throats, as an antiseptic vagina douche, and as
an anti-inflammatory cream and gel to treat soft tis-
sues (1–3). Recently, benzydamine was formulated
in a muco-adhesive gel designed for oral ulcers and
for radiation-induced mucositis of the oral, rectal,
or vaginal mucosa in cancer treatment (4, 5).
Photoallergic contact dermatitis from topical and
systemic benzydamine is known (1–3, 6, 7). Since
July 2006 after diagnosing a case of cheilitis as
a manifestation of photoallergic contact dermatitis
from benzydamine, this NSAID has been included
in our photoallergen patch test series and nine
additional cases of photoallergic contact dermatitis
have been diagnosed.
Patients and Methods
During a 3-year period (2006–2008), 74 patients (53
females/21 males) with photodermatoses or facial
dermatitis with aggravation following sun exposure
were patch tested with an extended baseline series
and photopatch tested with a photoallergen series
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Fig. 1. Subacute pruriginous cheilitis, with erythema and scaling on the lower lip and erosions in four patients.
Fig. 2. Lichenified eczema of the face, neck and the ‘V’ area of the upper chest, forearms, and dorsum of the hands in one patient.
that included sunscreens, salicylanilides and other
disinfectants, phenothiazines, and NSAIDs includ-
ing benzydamine (1 and 5% petrolatum (pet.) from
Bial-Aristegui®). In suspicious cases, patients were
also tested with the drug ‘as is’. Allergens were
applied in duplicate and irradiation of one set was
performed on D2 with 5 J/cm2 of UVA (Waldman®
7001K). Readings were performed at D2, within
30 min after irradiation and at D4, according to
ICDRG guidelines.
Results
A total of 10 patients (six females/four males), aged
between 21 and 84 (mean age 64.9 years) were
diagnosed as photoallergic contact dermatitis from
benzydamine. In nine patients there was a subacute,
pruriginous cheilitis, with erythema and scaling on
the lower lip in all patients and superficial erosions
in four patients (Fig. 1). Eczema extended to the
chin in seven patients, to the malar regions in three
and was associated with erythema or eczema on the
dorsum of the hands and forearms in two patients.
Lesions were recurrent and, for two patients, had
been occurring for more than 1 year. For 6 months,
one patient had a severe lichenified eczema of the
face, neck and the ‘V’ area of the upper chest,
forearms, and dorsum of the hands (Fig. 2).
All patients showed positive photopatch tests
(+ to +++) to benzydamine tested at 1 and 5%
and to benzydamine containing drugs (+ or +++)
(Table 1). No reactions were observed on non-
irradiated area to these allergens (Fig. 3). Additional
positive reactions were observed to fragrance mix
I and Myroxylon pereirae (one patient) and nickel
(three patients) (Table 1).
In the nine patients who had cheilitis, their histo-
ries showed long-term regular gargling with an oral
antiseptic solution containing 1.5% benzydamine
(Tantum verde®, Lepori Laboratories, Lisbon, Por-
tugal). Six of these patients had oral prostheses.
Two younger patients used the solution after the
fitting of an orthodontic device and their cheilitis
began within 2 months. An older patient with the
most extensive lesions had regularly applied a topi-
cal gel containing 3% benzydamine (Momen® gel,
Lepori Laboratories, Lisbon, Portugal) to his wife’s
back, for about 8 months. Two patients had been
on photoactive systemic drugs (amiodarone and
hydrochlorothiazide) for more than 2 years and they
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gel® Other patch test results
1 F 84 L, C NT + + NT Myroxylon pereriae, fragrance mix 1
2 M 77 L, C, M, H, F NT ++ ++ NT –
3 F 63 L, C, H, F NT ++ ++ ++ Nickel
4 M 71 L, C, M NT ++ ++ NT –
5 F 21 L ++ ++ ++ NT –
6 F 57 L, C ++ ++ ++ ++ –
7 M 81 LE NT +++ NT NT Nickel
8 F 72 L, C ++ ++ ++ +++ –
9 M 74 L NT ++ ++ NT –
10 F 49 L, C, M NT ++ ++ ND Nickel
C, chin; F, forearms; H, hands; LE, lichenified eczema on photo-exposed areas; L, lower lip; M, malar region; NT, not tested.
Fig. 3. Positive photopatch tests to benzydamine, Tantum verde® and Momen® gel, with negative results on non-irradiated area.
continued with no change in their doses. Lesions
disappeared within a few days/weeks after benzy-
damine discontinuation, with no case of persistent
photosensitivity. Therefore, all the reactions were
considered relevant. Also, none of the other 64
patients photopatch tested with benzydamine had a
positive result.
Discussion
Benzydamine has been shown to have phototoxic
properties in vitro and to cause both phototoxic-
ity and photoallergy (8). In this study, positivity of
the photopatch test with benzydamine at 1% pet.,
the absence of reactions in the other 64 patients
who were photopatch tested at 5% pet. during this
period, suggest these reactions are mainly photoal-
lergic. Also, they were all considered relevant, with
rapid improvement on drug discontinuation. The use
of the gargling solution may explain the main local-
ization on the lower lip and chin.
Although benzydamine is widely used (1, 3, 7)
and it is a known photosensitizer, with several pub-
lished cases in the 1980s and 1990s (9, 10), even
at our clinic (6) there are few recent reports of
photoallergic contact dermatitis from benzydamine
(2, 3, 11). This may be because of the unusual pre-
sentation which does not suggest photosensitivity;
the great majority of our patients presented with der-
matitis involving mainly the lower lip and chin. Pho-
toallergic contact dermatitis from benzydamine has
presented as hand dermatitis from using a vaginal
douche (2). Therefore, UV-irradiation of the patch
tests with the mouth wash products used by the
patient in cases of cheilitis is not the usual prac-
tice. As a result of its widespread use as a mouth
wash, we suggest benzydamine should be included
in a photopatch test series for patients being inves-
tigated for cheilitis.
Under-reporting of photosensitivity from benzy-
damine may also occur, because this NSAID is
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not part of most photoallergen series, and without
a good history of benzydamine use it may be
missed. In a recent study from Spain, where benzy-
damine was included in a photopatch testing series,
it was the second most frequent photoallergen, after
ketoprofen (12) and, in a recent report from our
department, benzydamine, tested only during the
latter years of the study, was one of the main pho-
toallergens, after piroxicam and promethazine (6).
Cross-reactions with other NSAIDs have been
suggested in one case (7), but, even though we did
not test indomethacin, none of our patients reacted to
other NSAIDs tested (ketoprofen, naproxen, ibupro-
fen, piroxicam, tenoxicam, and diclofenac).
Percutaneous or peroral absorption of this NSAID
may have caused lesions at distant sites, as observed
in four of our patients. There is a possibility
that connubial photoallergic contact dermatitis as
described for another NSAID, namely for ketopro-
fen (13, 14), may occur.
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